To identify genes whose deficiency confers drug resistance to the PARPi olaparib, we performed a genome-wide CRISPR genetic screen in MDA-MB-436 cells, a human breast cancer line harboring a BRCA1 mutation and which is sensitive to PARPi15. This evidence concerns the gene BRCA1 and breast cancer.